The economic impact of pre-dialysis epoetin alfa on health care and work loss costs in chronic kidney disease: An employer's perspective

Disease Management

Volumn 11, Issue 1, 2008, Pages 49-58

  Moyneur, Érick ^a   Bookhart, Brahim K ^b   Mody, Samir H ^b   Fournier, Andrée Anne ^a   Mallett, David ^c   Duh, Mei Sheng ^a,d  

^a ANALYSIS GROUP   (United States)

^b Ortho Biotech Products LP   (United States)

^c Ingenix Inc   (United States)

^d ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ABSENTEEISM; ADULT; ANEMIA; ARTICLE; BILLING AND CLAIMS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEMOGRAPHY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; UNIVARIATE ANALYSIS;

AGED; ANEMIA; COSTS AND COST ANALYSIS; DISABILITY EVALUATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSURANCE CLAIM REVIEW; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 39449093969     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2008.111715     Document Type: Article

References (25)

1. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38:803-812.
2. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002;162:1401-1408.
3. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501-1510.
4. National Kidney Disease Education Program. Chronic Kidney Disease in the United States. Available at: 〈www.nkdep.nih.gov/resources/ nkdep_ckd_presentation.ppt〉. Last accessed on December 10, 2007.
5. United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
6. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-554.
7. Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62:229-236.
8. Nissenson AR. Economic burden of anemia in an insured population. JMCP. 2005;11:565-574.
9. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8:629-638.
10. The NESP Usage Guidelines Group. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant. 2001;16(suppl 3):22-28.
11. Cameron JS. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999;14(suppl 2):61-65.
12. Brophy DF, Ripley EBD, Holdford DA. Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease. Expert Opin Pharmacother. 2003;4:1461-1469.
13. Kausz AT, Steinberg EP, Nissenson AR, Pereira BJG. Prevalence and management of anemia among patients with chronic kidney disease in a health maintenance organization. Dis Manag Health Outcomes. 2002;10:505-513.
14. Obrador GT, Pereira BJG. Anemia of chronic kidney disease: an underrecognized and under-treated problem. Nephrol Dial Transplant. 2002;17(suppl 11):44-46.
15. London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002;40:539-548.
16. Gouva C. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66:753-760.
17. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-185.
18. Dean BB, Dylan M, Gano A, Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin. 2005;21:981-987.
19. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001;16:307-312.
20. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079. discussion 1081-1090.
21. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (Review). The Cochrane Library. 2006;1.
22. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther. 2003;25:1786-1805.
23. Messa P, Nicolini MA, Cesana B, et al. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients. Nephrol Dial Transplant. 2006;21:431-436.
24. Cody J, Daly C, Campbell M, et al. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev. 2002;(4):CD003895.
25. Besarab A, Levin A. Defining a renal anemia management period. Am J of Kidney Dis. 2000;36(6 suppl 3):S13-S23.